Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Trimmed by Nuance Investments LLC

Nuance Investments LLC lessened its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 53.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 312,867 shares of the medical equipment provider’s stock after selling 352,580 shares during the period. Nuance Investments LLC owned about 0.13% of Hologic worth $23,230,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Hologic in the 4th quarter valued at about $217,529,000. Cetera Investment Advisers boosted its stake in Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after acquiring an additional 13,380 shares during the period. Nordea Investment Management AB grew its holdings in shares of Hologic by 1.3% during the first quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock valued at $116,797,000 after purchasing an additional 19,680 shares during the last quarter. Pinebridge Investments L.P. grew its holdings in shares of Hologic by 39.8% during the fourth quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock valued at $28,384,000 after purchasing an additional 113,050 shares during the last quarter. Finally, Clearbridge Investments LLC raised its position in shares of Hologic by 51.4% during the 1st quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after purchasing an additional 176,006 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.5 %

Hologic stock opened at $80.42 on Friday. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67. The stock has a market capitalization of $18.68 billion, a PE ratio of 41.03, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. The firm has a 50 day simple moving average of $80.06 and a 200-day simple moving average of $76.78. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period last year, the firm earned $0.93 EPS. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, equities research analysts expect that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insider Activity

In related news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Hologic news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,280 shares of company stock worth $1,469,973. Insiders own 1.75% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Evercore ISI upped their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. StockNews.com raised shares of Hologic from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Stephens reissued an “overweight” rating and set a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research note on Friday, August 16th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.